Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Adial Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

GLEN ALLEN, VA., OCT. 17, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY ANNOUNCED THAT CARY CLAIBORNE, CEO OF ADIAL, WAS INVITED TO APPEAR AS A FEATURED GUEST ON THE BIG BIZ SHOW, AN EMMY AWARD-WINNING NATIONALLY SYNDICATED RADIO AND TV PROGRAM.

ADIAL PHARMACEUTICALS CEO WAS A FEATURED GUEST ON THE BIG BIZ SHOW

PARTNERSHIP HAS SUCCESSFULLY COMPLETED ANALYTICAL VALIDATION OF A CHEEK SWAB COLLECTION SOLUTION FOR TESTING AND IDENTIFYING PATIENTS WITH THE GENOTYPES IMPORTANT FOR AD04 DEVELOPMENT PARTNERSHIP HAS SUCCESSFULLY COMPLETED ANALYTICAL VALIDATION OF A CHEEK SWAB COLLECTION SOLUTION FOR TESTING AND IDENTIFYING PATIENTS WITH THE GENOTYPES IMPORTANT FOR AD04 DEVELOPMENT

ADIAL PHARMACEUTICALS PARTNERS WITH GENOMIND FOR PRECISION MEDICINE TESTING SOLUTION

FDA MINUTES REFLECT CONSTRUCTIVE DIALOGUE AND SUCCESSFUL MEETING OUTCOME WITH ALIGNMENT ON UPCOMING PHASE 3 CLINICAL TRIAL DESIGN FOR AD04 IN ALCOHOL USE DISORDER FDA MINUTES REFLECT CONSTRUCTIVE DIALOGUE AND SUCCESSFUL MEETING OUTCOME WITH ALIGNMENT ON UPCOMING PHASE 3 CLINICAL TRIAL DESIGN FOR AD04 IN ALCOHOL USE DISORDER

ADIAL PHARMACEUTICALS PROVIDES BUSINESS UPDATE FOLLOWING FAVORABLE COMMENTS FROM FDA END-OF-PHASE 2 (EOP2) MEETING FOR AD04

GLEN ALLEN, VA., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY ANNOUNCED THAT IT HAS BEEN GRANTED A 180 CALENDAR DAY EXTENSION FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) TO REGAIN COMPLIANCE WITH THE NASDAQ'S MINIMUM $1.00 BID PRICE REQUIREMENT SET FORTH IN NASDAQ LISTING RULE 5550(A)(2) (THE RULE) FOR CONTINUED LISTING ON NASDAQ (THE MINIMUM BID PRICE REQUIREMENT), FOLLOWING THE EXPIRATION OF THE INITIAL 180 CALENDAR DAY PERIOD TO REGAIN COMPLIANCE ON SEPTEMBER 1, 2025, WHICH WAS INITIALLY GRANTED ON MARCH 5, 2025.

ADIAL PHARMACEUTICALS GRANTED A 180 CALENDAR DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH THE MINIMUM BID PRICE RULE

GLEN ALLEN, VA., AUG. 14, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025.

ADIAL PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

MEETING COMPLETION MARKS MAJOR STEP TOWARD PHASE 3 AD04 TRIAL LAUNCH STRATEGIC PARTNERSHIP DISCUSSIONS EXPECTED FOLLOWING THE POSITIVE FDA MEETING GLEN ALLEN, VA., AUG. 06, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY ANNOUNCED THE COMPLETION OF A SUCCESSFUL END OF PHASE 2 MEETING (EOP2M) WITH THE FOOD AND DRUG ADMINISTRATION (FDA).

ADIAL PHARMACEUTICALS COMPLETES SUCCESSFUL EOP2 FDA MEETING

GLEN ALLEN, VA., JULY 16, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY ANNOUNCED THAT IT RECEIVED NOTICE FROM NASDAQ ON JULY 14, 2025 THAT THE COMPANY HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE 5550(B)(1), WHICH REQUIRES LISTED COMPANIES TO MAINTAIN STOCKHOLDERS' EQUITY OF AT LEAST$2,500,000.

ADIAL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ STOCKHOLDERS' EQUITY LISTING REQUIREMENT

GLEN ALLEN, VA., JULY 09, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, ANNOUNCED THE FILING OF AN UPDATE TO THE PROVISIONAL PATENT APPLICATION FOR AD04 WHICH WAS FILED IN JULY 2024, THE COMPANY'S LEAD INVESTIGATIONAL GENETICALLY TARGETED, SEROTONIN-3 RECEPTOR ANTAGONIST, THERAPEUTIC AGENT FOR THE TREATMENT OF ALCOHOL USE DISORDER (AUD) IN HEAVY DRINKING PATIENTS (DEFINED AS < 10 DRINKS/DRINKING DAY).

ADIAL PHARMACEUTICALS FILES PCT PATENT APPLICATION TO PROTECT CORE ASSETS AND EXTEND IP EXCLUSIVITY ON CORE TECHNOLOGY TO AT LEAST 2045

SCOPE OF AGREEMENT WITH CAMBREX TO PROVIDE ONDANSETRON HCL DRUG SUBSTANCE UNDER FDA APPROVED DRUG MASTER FILE SCOPE OF AGREEMENT WITH THERMO FISHER TO PROVIDE MANUFACTURING SERVICES INCLUDING DEMONSTRATION, CLINICAL, REGISTRATION AND VALIDATION BATCHES OF AD04 FOR US CLINICAL TRIALS AND NDA SUBMISSION GLEN ALLEN, VA., JUNE 25, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY ANNOUNCED THE RECENT EXECUTION OF AGREEMENTS FOR THE PRODUCTION OF AD04 (0.33 MG ONDANSETRON TABLETS), SUPPORTING BOTH THE COMPLETION OF UPCOMING CLINICAL TRIALS AND THE PLANNED NEW DRUG APPLICATION (NDA) SUBMISSION TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF ALCOHOL USE DISORDER (AUD) IN THE US.

ADIAL PHARMACEUTICALS SECURES U.S.-BASED MANUFACTURING THROUGH AGREEMENTS WITH CAMBREX AND THERMO FISHER SCIENTIFIC FOR DRUG SUBSTANCE AND DRUG PRODUCT SUPPLY

GLEN ALLEN, VA., MAY 15, 2025 (GLOBE NEWSWIRE) -- ADIAL PHARMACEUTICALS, INC. (NASDAQ: ADIL) (ADIAL OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPIES FOR THE TREATMENT AND PREVENTION OF ADDICTION AND RELATED DISORDERS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025.

Adial Pharmaceuticals, Inc.

ADIL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Adial Pharmaceuticals, Inc.

ADIL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ADIL